Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crizanlizumab in sickle cell disease patients with priapism
NCT03938454Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2019
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of crizanlizumab in Priapism, sponsored by Novartis. Primary endpoint: Percent Change in Priapic Events From Baseline to 26 Weeks. Started Oct 2019; status: completed.
02
Drugs
crizanlizumab
03
Conditions
Priapism
Beyond the preview
Go deeper on NCT03938454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03938454.